Clearside Biomedical, Inc. Announces Ongoing Results in Phase 1/2 Clinical Trial in Patients with Non-infectious Uveitis

Print 15 October 2014

Regarding best-corrected visual acuity (BCVA), all eight patients have shown clinically meaningful improvement of five or more letters in BCVA at week 8, while five of the eight patients have improved by at least 15 letters at week 8.

The suprachoroidal injection of triamcinolone acetonide appeared generally well tolerated in all eight patients in this study. No patient in the study has experienced a clinically meaningful increase in intraocular pressure, a commonly known complication associated with intraocular or periocular administration of corticosteroids.

About Uveitis

Uveitis is one of the most frequent causes of blindness in the developed world. Based on prevalence data published in the journal Ophthalmology in 2004 and United States census data for 2010, it is estimated approximately 350,000 individuals in the United States suffer from some form of uveitis. Typically diagnosed in individuals between the ages of 20 and 50, uveitis can occur in one or both eyes and accounts for approximately 10% of cases of blindness in the United States, according to a study published in Journal of Ophthalmology. Uveitis can be either infectious or non-infectious. Non-infectious uveitis accounts for approximately 80% of all uveitis cases. Macular edema related to uveitis is the predominant cause of blindness or visual impairment among patients with uveitis, accounting for approximately 30% of cases of blindness in uveitis patients. Because uveitis can become chronic or recurrent if not adequately treated, some patients may become refractory, or unresponsive, to treatment, leading to irreversible blindness.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema. Visit www.clearsidebio.com for more information.

Return

All Portfolio

MEDIA CENTER